OwnersBox Launches Daily Fantasy Sports Games in Pennsylvania
Newswire Launches Media Database Subscriptions to Further Enhance the Value of Press Release Distribution
K12 Technology Company Edlio Acquires SchoolInfo, Launches Edlio Access App
Essential Education Brings MindPlay to Adult Education
Instawork Staffs Stadiums Across the Country as Football Season Kicks Off
Lions Legacy Club Becomes First NIL Collective Dedicated to Penn State Football
The Harris Poll Discusses ‘Quiet Quitting’ Becoming Businesses’ Greatest Fear and Management Challenge in...
The Quiet Quitting movement is both "business leaders' biggest fear" and a challenge that they alone can solve, according to Libby Rodney, chief strategy officer at The Harris Poll Thought Leadership Practice. Rodney shared her thoughts on the trend in an August episode of the new podcast "America This Week," co-hosted by Rodney and John Gerzema, CEO of The Harris Poll.
During their conversation, Rodney and Gerzema explore the origins of the Quiet Quitting movement, which leaped from TikTok to international headlines in The New York Times, The Wall Street Journal and The Guardian. They explore who's disengaging, and why, and delve into the rise of free agent employees who want more money from corporations at a time when those corporations are more likely to instigate hiring freezes and layoffs.
Despite its name, Quiet Quitting doesn't actually involve quitting, per se. "You're not outright quitting your job, but you're quitting the idea of going above and beyond," said TikTok user Zaiad Khan. As described by BBC News, Quiet Quitting means "doing only what your job demands and nothing more. Quitting doing anything extra. You still show up for work, but stay strictly within the boundaries of your job requirements. So no more helping out with additional tasks or checking emails outside work hours."
A new survey that Harris Poll conducted for Bloomberg News examines the factors that contribute to Quiet Quitting. The poll revealed that in general, the younger the worker, the more disillusioned they are with their jobs and the more likely they are to quit if employers implement return-to-office (RTO) policies and reduce hybrid or work-from-home (WFH) environments.
Among the findings:
Employers Hold the Reins: More than three-quarters (76%) of Gen Z employees believe employers have more leverage in the job market than employees, compared to 56% of all employees.
Young People Are Free Agents: Among working adults, 42% of Gen Z and 37% of Millennials have recently quit or switched jobs in the past two years; 48% of Gen Z and 49% of Millennials say they are likely to quit their job in the next year.
Fearing the Worst: Among working adults, 57% of Gen Z and 42% of Millennials are worried that they are going to lose their job soon.
Fight vs. Flight: Almost two-thirds (66%) of Millennials say they have stayed in their jobs because of economic fluctuations (e.g., rising inflation, decreasing stock market) compared to barely half (51%) of Gen Z.
Bracing for RTO: Among remote/hybrid working adults, 57% of Millennials say they would quit if they were forced to work five days a week in the office.
Ready to Jump: Seven in 10 (71%) of Gen Z and more than two-thirds (68%) of Millennials say they are likely to try securing other job offers in order to get raises at their current jobs.
Those signs of career unhappiness are behind the Quiet Quitting movement and are why employers are concerned about productivity.
"One thing to recognize is that this is most business leaders' biggest fear," Rodney said during the podcast. "This is exactly what they're worried about and why they're telling people to return to the office.
"The second [thing], and the most important one, is the context of this. Before the pandemic, the employee engagement rates were really low. There was a massive burnout in workplace culture, and even the World Health Organization deemed it a critical thing that corporate workplaces had to solve. The pandemic just put fuel on that, and we all had to run and sprint through this time, and maybe now we're in more of a marathon. It's up to companies to get people excited to be working."
Rodney and Gerzema dig much deeper into the topic, offering more insight as well as statistics during their discussion of Quiet Quitting, which can be heard at
https://podcasts.apple.com/us/podcast/america-this-week-from-the-harris-poll/id1626151653
For additional information about the Harris Poll Thought Leadership Practice, visit:
https://theharrispoll.newswiremap.com
About Harris Poll Thought Leadership Practice
Building on 50+ years of experience pulsing societal opinion, we design research that is credible, creative, and culturally relevant. Our practice drives thought leadership and unearths trends for today's biggest brands. We are focused on helping our clients get ahead of what's next.
Media Contact
Madeleine Moench
[email protected]
Press Release Service by Newswire.com
Original Source: The Harris Poll Discusses 'Quiet Quitting' Becoming Businesses' Greatest Fear and Management Challenge in New Podcast Episode
South Korea’s CD BIO Seeks Clinical Trial, FDA Registration for Its VOCs Biosensing Kit...
LOS ANGELES - September 5, 2022 - (Newswire.com)
Korean technicians announced on the 30th that they have developed a diagnostic device that diagnoses lung cancer from breathing tests. They have plans to submit the device for U.S. FDA approval and conduct further clinical trials.
To reduce the death rate that is increasing due to cancer, Korean company CD BIO's CEO, Baek Kyung-jin, has developed a diagnostic device VOCs Biosensing Kit that detects lung cancer and various cancers at an early stage with a simple breathing test.
Globalian, a company that opens up export opportunities and conducts export voucher programs with support from the Korean Academy of Clinical Health and the Korean government, has initiated FDA registration and the clinical trial process for CD BIO's VOCs Biosensing Kit through an export voucher program, collaborating with International Licensing Research Solutions, LLC (ILRS) and American Technology Clinical Solutions, Inc. (ATCS). ILRS and ATCS are collaborating, acting as U.S. agents for CD BIO, overseeing all aspects of international marketing.
The clinical trial on the effectiveness of detecting lung cancer and various cancers at an early stage with a simple breathing test was successful, and the thesis presentation was conducted. Now, the company is preparing for a clinical trial with a credible institution for follow-up tests, and at the same time planning to submit for FDA review in the United States in order to advance in the markets in the United States.
CD BIO's CEO, Baek Kyung-jin, said, "Through this clinical trial and the U.S. FDA [review] process, we will play the role of a tool to save people by combining the talents that God has given us with technology. It is the path that I have been praying for until now, and I believe that he will lead me in the future."
Next, he thanked all the technical staff and researchers who participated in the development and said that he will obtain the sober judgment and clear technology direction of the FDA.
Catherine Young
[email protected]
Press Release Service by Newswire.com
Original Source: South Korea's CD BIO Seeks Clinical Trial, FDA Registration for Its VOCs Biosensing Kit That Detects Early Stage Lung and Other Cancers With Simple Breathing Test
The Oligonucleotide Therapeutics Society’s Highly Anticipated Annual Meeting Returns in Person This Year
OTS is pleased to announce that, after two years of meeting virtually, the 18th Annual Oligo Meeting will include a robust in-person program live from Hilton Phoenix Resort at the Peak in Phoenix, Arizona, where delegates from many different countries can engage in lively discussions and enjoy interacting face-to-face once again. This year's meeting, which will be held Oct. 2 - 5, is a hybrid event and will also include a virtual component allowing delegates who are unable to attend in person to enjoy the Annual Meeting from the comfort of their home or office.
The Oligonucleotide Therapeutics Society (OTS) is an open, nonprofit forum to foster academic and industry-based research and development of oligonucleotide therapeutics. The Founders' vision was to bring together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.
The OTS Annual Meeting is a forum for the realization of the Society's mission and goals. At the annual meeting, anyone who is interested or involved in oligonucleotide therapeutics may attend and benefit from the incredible opportunity to learn from and engage with experts, post-docs, and students for a cross-disciplinary exchange, fostering the development of ground-breaking new ideas.
Due to the efforts and persistence of those in the field, multiple oligonucleotide therapeutic treatments have received approval from regulatory agencies around the world, two mRNA Covid-19 vaccines were created due to decades of prior development in the field, and over 100 oligonucleotide therapeutic treatments are in development for common conditions, including cancer and Alzheimer's disease, as well as rare diseases. Incredibly, oligonucleotide therapeutics are being used to create individualized treatments for people with ultra-rare, fatal diseases.
Attendees of this year's Oligo Meeting will hear from leading experts, students, and postdocs in the field from around the world. An array of intriguing topics will be covered, from chemistry, AI/machine learning, and genome and RNA editing to current preclinical and clinical research.
The Clinical Session is always engaging and inspiring, and this year's session promises to continue the trend with topics such as Clinical Advances in CRISPR Cas9 Therapeutics, SLN360 and Controlling Lp(a), and Lessons Learned from ALS Clinical Trials. Speakers include notable authorities in the field at key roles in Biogen, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Intellia Therapeutics, Silence Therapeutics, and n-Lorem Foundation.
A special session is dedicated to celebrating the 20th anniversary of the Oligonucleotide Therapeutics Society, and attendees will have the privilege of hearing from founders of the OTS as well as past Board of Directors members who were there during the early days of the society, including Masad J. Damha, PhD, Gunther Hartmann, MD, PhD, Anastasia Khvorova, PhD, Art Krieg, MD, Mano Manoharan, PhD, Brett Monia, PhD, John Rossi, PhD, Georg Sczakiel, PhD, Hermona Soreq, PhD, and Cy Stein, MD, PhD.
OTS also has the privilege of presenting two OTS Lifetime Achievement Awards this year to individuals who have been influential in the field. Ryszard Kole, PhD, Professor Emeritus at the University of North Carolina, will be honored with the OTS Lifetime Achievement Award 2020 and C. Frank Bennett, PhD, the Senior Vice President of Research at Ionis Pharmaceuticals, will be honored with the OTS Lifetime Achievement Award 2021.
The Annual Meeting is open to anyone interested or involved in oligonucleotide therapeutics. Those wishing to attend in person or virtually can register at 2022oligomeeting.com.
Media Contact:
Geri Beaty
Phone: (619) 795-9458
Email: [email protected]
Press Release Service by Newswire.com
Original Source: The Oligonucleotide Therapeutics Society's Highly Anticipated Annual Meeting Returns in Person This Year
The Worlds Most Expensive Bentley on Reality TV Show
Debbie Wingham, world renowned for creating countless of the world’s most expensive things herself, recently landed her own reality show on Gossip Stone TV, a media company producing several reality TV shows featuring celebrities, glitz, and glamour. To date Wingham has created 13 one-of-a-kind elaborate commissions, most of which also carry the title of being […] 